stockrowZymeworks Inc.
ZYME Healthcare Biotechnology
Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024.
- Revenue
- −90.6%
- EPS
- −2,166.7%
- Free cash flow
- −385.5%
Quarter to June 2026, against a year earlier
Follow ZYME
Alert me
Zymeworks Inc. (ZYME) Shares outstanding
Zymeworks Inc.'s shares outstanding at the end of fiscal 2025 was $75.4M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $73.0M. Over the past ten years it has ranged from $12.7M (fiscal 2016) to $75.9M (fiscal 2024); the current reading is higher than 91% of that period. Zymeworks Inc. ranks 205th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $75.4M | (0.61%) |
| FY2024 | $75.9M | 10.19% |
| FY2023 | $68.9M | 5.54% |
| FY2022 | $65.2M | 25.16% |
| FY2021 | $52.1M | 3.47% |
| FY2020 | $50.4M | 32.51% |
| FY2019 | $38.0M | 30.70% |
| FY2018 | $29.1M | 36.44% |
| FY2017 | $21.3M | 67.40% |
| FY2016 | $12.7M | (52.63%) |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $73.0M | (2.28%) |
| Mar 2026 | $74.7M | (0.95%) |
| Dec 2025 | $75.4M | (0.48%) |
| Sep 2025 | $75.8M | (2.07%) |
| 38 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| BHVN Biohaven Ltd. compare | $151.0M |
| AUPH Aurinia Pharmaceuticals Inc compare | $135.2M |
| IMNM Immunome, Inc. compare | $113.3M |
| ZYME Zymeworks Inc. | $73.0M |
| VERA Vera Therapeutics, Inc. compare | $71.8M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | $65.9M |
| VCEL Vericel Corporation compare | $53.0M |
| SEPN Septerna, Inc. compare | $45.0M |
| COAG Hemab Therapeutics Holdings, Inc. compare | $30.1M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on ZYME
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement